摘要
目的本文旨在对银杏叶提取物(ginkgo biloba extract,GBE)相互作用机理进行系统、深入地分析,阐明易发生相互作用的银杏叶提取物中单体成分,为临床银杏叶提取物合并用药提供依据,同时为其他含有这些单体成分的中药相互作用研究提供理论依据。方法结合相关文献38篇,对目前银杏叶提取物及其单体成分药物相互作用机理进行深入总结。结果与结论银杏叶提取物是治疗心血管类疾病的常用药物,常与抗血小板、镇静、降压、降脂类等药物联合应用。银杏及其单体成分槲皮素、山柰酚及异鼠李素等黄酮类成分对CYP3A4、CYP2C9、CYP2B6等具有抑制作用,而其单体成分银杏内酯A、B及白果内酯等内酯类成分对CYP1A2、CYP2B1/2、CYP3A2、CYP2C19、UGT1A1等又具有诱导作用,且为P-糖蛋白底物,与药物合用易引发药物相互作用,且作用复杂,因此需引起广泛重视。
Objective To indepth analysis of ginkgo biloba extract interaction mechanism systematically, to clarify which isolated components of gingkgo biloba extract easily lead to the interaction, to provide the basis for clinical drug combined with ginkgo biloba extract, as well as to provide a theoretical basis for studies on drug interaction of other Chinese medicine containing these isolated components. Methods According to 38 related literature, drug interaction mechanism of ginkgo biloba extract and its isolated components were con- cluded and depth summarized. Results and Conclusions Ginkgo biloba extract is commonly used to treat car- diovascular diseases which often associated with anti-platelet drugs, sedative drugs, antihypertensive, lipid- lowering drugs. CYP3A4 ,CYP2C9 ,CYP2B6 are inhibited by GBE and its isolated components-flavonoids, such as quercetin, kaempferol and isorhamnetin （ the P-glycoprotein substrates）, while CYP1A2, CYP2B1/ 2, CYP3A2, CYP2C19, etc. are induced by its isolated components-lactones, such as ginkgolide A, B, and bi- lobalide, so GBE and its isolated components associated with the drugs easily lead to drug interactions and therefore require widespread attention.
出处
《沈阳药科大学学报》
CAS
CSCD
北大核心
2014年第3期217-223,共7页
Journal of Shenyang Pharmaceutical University
